Search Results - "SCHWID, S"

Dose comparison trial of sustained-release fampridine in multiple sclerosis by GOODMAN, A. D, BROWN, T. R, COHEN, J. A, KRUPP, L. B, SCHAPIRO, R, SCHWID, S. R, COHEN, R, MARINUCCI, L. N, BLIGHT, A. R

“…To examine the efficacy and safety of three different doses of sustained-release fampridine in people with multiple sclerosis (MS). This multicenter,…”
Get full text

Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis by KRUPP, L. B, CHRISTODOULOU, C, SCHWID, S. R, WEINSTOCK-GUTTMAN, B, WESTERVELT, H. J, WISHART, H, MELVILLE, P, SCHERL, W. F, PAI, L.-Y, MUENZ, L. R, HE, D, BENEDICT, R. H. B, GOODMAN, A, RIZVI, S

“…The goal of this study was to determine if memory would be improved by donepezil as compared to placebo in a multicenter, double-blind, randomized clinical…”
Get full text

Cost-effectiveness of disease-modifying therapy for multiple sclerosis: A population-based study by NOYES, K, BAJORSKA, A, CHAPPEL, A, SCHWID, S. R, MEHTA, L. R, WEINSTOCK-GUTTMAN, B, HOLLOWAY, R. G, DICK, A. W

“…To evaluate the cost-effectiveness of disease-modifying therapies (DMTs) in the United States compared to basic supportive therapy without DMT for patients…”
Get full text

Quantitative risk-benefit analysis of natalizumab by THOMPSON, J. P, NOYES, K, DORSEY, E. R, SCHWID, S. R, HOLLOWAY, R. G

“…To model the long-term risks and benefits of natalizumab in individuals with relapsing multiple sclerosis (MS). We created a Markov model to evaluate treatment…”
Get full text

Assessing disability progression with the Multiple Sclerosis Functional Composite by Rudick, RA, Polman, CH, Cohen, JA, Walton, MK, Miller, AE, Confavreux, C, Lublin, FD, Hutchinson, M, O’Connor, PW, Schwid, SR, Balcer, LJ, Lynn, F, Panzara, MA, Sandrock, AW

“…Background The initial Multiple Sclerosis Functional Composite (MSFC) proposal was a three-part composite of quantitative measures of ambulation, upper…”
Get full text

MRI features of pediatric multiple sclerosis by Banwell, B, Shroff, M, Ness, J M, Jeffery, D, Schwid, S, Weinstock-Guttman, B

“…MRI has revolutionized the diagnostic accuracy of multiple sclerosis (MS) in adults, and is now used extensively to evaluate efficacy of immunomodulatory…”
Get full text

Quantitative functional measures in MS: What is a reliable change? by SCHWID, S. R, GOODMAN, A. D, MCDERMOTT, M. P, BEVER, C. F, COOK, S. D

“…As a first step toward understanding which changes should be considered as meaningful, the authors assessed the reliability of quantitative functional tests on…”
Get full text

Safety of rasagiline in elderly patients with Parkinson disease by GOETZ, C. G, SCHWID, S. R, EBERLY, S. W, OAKES, D, SHOULSON, I

“…The authors examined age effects on adverse events from two randomized, controlled trials of rasagiline, comparing younger (younger than 70 years) and older…”
Get full text

Randomized controlled trial of atorvastatin in clinically isolated syndrome: The STAyCIS study by WAUBANT, E, PELLETIER, D, SCHWID, S, GOODMAN, A, KACHUCK, N, PREININGEROVA, J, WEINSTOCK-GUTTMAN, B, CALABRESI, P. A, MILLER, A, MOKHTARANI, M, IKLE, D, MURPHY, S, MASS, M, KOPETSKIE, H, DING, L, ROSENBERG, E, SPENCER, C, ZAMVIL, S. S, COHEN, J. A, KITA, M, CROSS, A, BAR, A, VOLLMER, T, RACKE, M, STIIVE, O

“…To test efficacy and safety of atorvastatin in subjects with clinically isolated syndrome (CIS). Subjects with CIS were enrolled in a phase II, double-blind,…”
Get full text

Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis by DORSEY, E. R, THOMPSON, J. P, NOYES, K, DICK, A. W, HOLLOWAY, R. G, SCHWID, S. R

“…Using published data, we quantified the risk and benefits of natalizumab in relapsing multiple sclerosis using quality-adjusted life years (QALYs) as a metric…”
Get full text

Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment by Polman, C H, Reingold, S C, Barkhof, F, Calabresi, P A, Clanet, M, Cohen, J A, Cutter, G R, Freedman, M S, Kappos, L, Lublin, F D, McFarland, H F, Metz, L M, Miller, A E, Montalban, X, O'Connor, P W, Panitch, H, Richert, J R, Petkau, J, Schwid, S R, Sormani, M P, Thompson, A J, Weinshenker, B G, Wolinsky, J S

“…The increasing number of established effective therapies for relapsing multiple sclerosis (MS) and emerging consensus for early treatment raise practical…”
Get full text

The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD

“…CEP-1347 is an inhibitor of members of the mixed lineage kinase family, key signals triggering apoptotic neuronal death. The authors performed a randomized,…”
Get full text

Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis by SCHWID, S. R, PETRIE, M. D, MCDERMOTT, M. P, TIERNEY, D. S, MASON, D. H, GOODMAN, A. D

“…To evaluate the efficacy of 4-aminopyridine sustained release (4AP SR) (fampridine, EL-970) using quantitative measures of motor function in multiple sclerosis…”
Get full text

Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms by Elmer, L., Schwid, S., Eberly, S., Goetz, C., Fahn, S., Kieburtz, K., Oakes, D., Blindauer, K., Salzman, P., Oren, S., Prisco, U.L., Stern, M., Shoulson, I.

“…Cognitive and behavioral adverse events (AEs) such as hallucinations, confusion, depression, somnolence and other sleep disorders commonly limit effective…”
Get full text

Quantitative assessment of motor fatigue and strength in MS by SCHWID, S. R, THORNTON, C. A, PANDYA, S, MANZUR, K. L, SANJAK, M, PETRIE, M. D, MCDERMOTT, M. P, GOODMAN, A. D

“…To determine the test-retest reliability of strength and fatigue measurements in patients with MS and in healthy control subjects, and to examine associations…”
Get full text

Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium by WEINSTOCK-GUTTMAN, B, JACOBS, L. D, GOTTESMAN, M. H, HERBERT, J, HOLUB, R, LAVA, N. S, LENIHAN, M, LUSINS, J, MIHAI, C, MILLER, A. E, PEREL, A. B, SNYDER, D. H, BROWNSCHEIDLE, C. M, BAKSHI, R, GRANGER, C. V, GREENBERG, S. J, JUBELT, B, KRUPP, L, MUNSCHAUER, F. E, RUBIN, D, SCHWID, S, SMIROLDO, J, BAIER, M, REA, D. F, APATOFF, B. R, BLITZ, K. M, COYLE, P. K, FRONTERA, A. T, GOODMAN, A. D

“…The objective of this study was to determine the clinical characteristics of multiple sclerosis (MS) in African American (AA) patients in the New York State…”
Get full text

Proof of concept studies for tissue-protective agents in multiple sclerosis by Mehta, LR, Schwid, SR, Arnold, DL, Cutter, GR, Aradhye, S, Balcer, LJ, Calabresi, PA, Cohen, JA, Cole, PE, Glanzman, R, Goelz, S, Inglese, M, Kapoor, R, Kappos, L, Kreitman, R, Lublin, FD, Mann, A, Marrie, RA, O'Looney, P, Polman, CH, Ravina, BM, Reingold, SC, Richert, JR, Sandrock, AW, Waubant, E

“…Background There is considerable interest in tissue-protective treatments for multiple sclerosis (MS). Methods and Objectives We convened a group of MS…”
Get full text

Interferon beta-1a in children with multiple sclerosis is well tolerated by Waubant, E, Hietpas, J, Stewart, T, Dyme, Z, Herbert, J, Lacy, J, Miller, C, Rensel, M, Schwid, S, Goodkin, D

“…Multiple sclerosis is a chronic demyelinating disease rare in children. Currently marketed disease modifying therapies are limited to adults. To determine the…”
Get more information

The measurement of ambulatory impairment in multiple sclerosis by SCHWID, S. R, GOODMAN, A. D, MATTSON, D. H, MIHAI, C, DONOHOE, K. M, PETRIE, M. D, SCHEID, E. A, DUDMAN, J. T, MCDERMOTT, M. P

“…The objective of this study was to examine the relationships between continuous measures of ambulatory impairment in MS patients and their ordinal…”
Get full text

Are quantitative functional measures more sensitive to worsening MS than traditional measures? by SCHWID, S. R, GOODMAN, A. D, APATOFF, B. R, COYLE, P. K, JACOBS, L. D, KRUPP, L. B, MILLER, A. E, WENDE, K. E, BROWNSCHEIDLE, C. M

“…The authors used data collected prospectively during a multicenter trial in 133 patients with secondary progressive MS to assess the relative sensitivity of…”
Get full text